FibroKey Grant Program

FibroKey™ Grant Program:
Advancing Fibrosis Research Together

About the Program

The FibroKey™ Grant Program is an initiative by Inoviv to accelerate fibrosis research and empower the scientific community. This program offers the opportunity to leverage FibroKey™, Inoviv’s multiplexed proteomics platform, to analyze fibrosis biomarkers in up to 75 samples. The program is designed to support groundbreaking studies in fibrosis and chronic kidney disease (CKD), helping researchers and drug developers gain deeper insights into disease mechanisms.

This initiative reflects Inoviv’s commitment to improving healthcare outcomes through innovative biomarker research.

Application Deadline: December 23, 2024

Sample Submission Deadline: February 28, 2025

Sample Types: Primarily urine, though other matrices (e.g., plasma, serum) may be considered if technically feasible and scientifically valuable

Sample Requirements: A minimum of 0.5 ml per sample is required. Applicants must provide a cohort of at least 50 patients, with a minimum of 6 samples per group

Grant Award: FibroKey™ analysis of up to 75 human samples

Eligibility: Open to scientists at all levels, including PhD students and post-doctoral researchers, working in academic institutions and pharma companies globally

Program Duration: Selected applicants will be notified on a rolling basis, with public announcement of the grant winners

Applicants must submit their proposal through the online application form by December 10, 2024. The proposal should include a study overview, sample cohort description, and scientific impact of the research. Proposals will be evaluated based on study design, hypothesis robustness, and scientific value.

The Inoviv selection committee—comprised of five PhD-level proteomics experts—will review and score each application. Additional information or interviews may be requested from shortlisted candidates.

Applications are invited from scientists working in academic/research institutions or pharmaceutical companies.
The proposal should involve the analysis of human urine samples, though other matrices may be considered for studies of exceptional scientific value.
Samples must be shipped to Inoviv (UK) by February 28, 2025, at the awardee’s expense.
The awardee will have permission to use and publish the data generated.
Inoviv shall, in consultation with awardee, be able to utilize results in promotional materials.
Applicants must agree to Inoviv’s MSA and the FibroKey™ Grant Program’s terms.
The grant winner will be publicly announced following the review process.

Key Benefits of FibroKey™:

Comprehensive Biomarker Analysis
Measure 35 key fibrosis biomarkers involved in extracellular matrix (ECM) remodeling and inflammatory processes.

Multiplex Proteomics Platform
High-throughput analysis with Inoviv’s validated, mass spectrometry-based assay.

Sample Flexibility
Suitable for urine, plasma, and serum samples.

Scientific Support
Inoviv’s experts will provide data analysis, interpretation, and study design support to enhance your research outcomes.

Access the Application Form

Have Any Questions or Concerns?